Latest Attention-deficit hyperactivity disorder management Stories
PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch DaytranaÂ®.
Primary objective of the study was to evaluate the safety of coadministration of INTUNIV with stimulants.
PHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.
LAS VEGAS, Nov.
PLYMOUTH MEETING, Pa., Nov.
INTUNIV, recently approved by the FDA as the first nonscheduled alpha-2A agonist indicated for the treatment of ADHD in children and adolescents, will soon be available in pharmacies nationwide.
Following is a summary of the key Shire scientific presentations.
- One of the side scenes of the stage in a theater, or the space included between the side scenes.
- The outside stock exchange, or “curb market,” of Paris.
- A flute or groove on the blade of a sword.
- A section of stage scenery placed in a wing of a theatre.